VILLA, MATTEO
 Distribuzione geografica
Continente #
EU - Europa 597
NA - Nord America 368
AS - Asia 159
SA - Sud America 5
Totale 1.129
Nazione #
US - Stati Uniti d'America 365
IT - Italia 334
SG - Singapore 82
DE - Germania 78
IE - Irlanda 76
RU - Federazione Russa 43
HK - Hong Kong 33
CN - Cina 25
SE - Svezia 15
FI - Finlandia 12
GB - Regno Unito 10
ID - Indonesia 9
IN - India 7
PL - Polonia 6
NL - Olanda 5
PE - Perù 5
FR - Francia 4
BE - Belgio 3
BY - Bielorussia 2
CA - Canada 2
DK - Danimarca 2
MK - Macedonia 2
TH - Thailandia 2
BG - Bulgaria 1
CH - Svizzera 1
CZ - Repubblica Ceca 1
KR - Corea 1
PR - Porto Rico 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 1.129
Città #
Milan 117
Ann Arbor 96
Dublin 75
Singapore 69
Frankfurt am Main 65
New York 37
Chandler 33
Hong Kong 32
Santa Clara 23
Fairfield 20
Ashburn 16
Rome 16
Carate Brianza 15
Monza 13
Beijing 10
Desio 10
Lissone 10
Helsinki 9
Jakarta 9
Shanghai 8
Cesano Maderno 7
Genoa 7
San Diego 7
Wilmington 7
Lodz 6
Munich 6
Princeton 6
Romola 6
Houston 5
Lima 5
Los Angeles 5
Sesto San Giovanni 5
Assago 4
Bergamo 4
Chicago 4
Vercelli 4
Ardea 3
Arese 3
Brussels 3
Cinisello Balsamo 3
Lappeenranta 3
Lawrence 3
London 3
Marano di Napoli 3
Marino 3
Osio Sotto 3
Portici 3
Alexandria 2
Andover 2
Bangkok 2
Bari 2
Bhopal 2
Boardman 2
Bolzano 2
Bonndorf 2
Bradford 2
Cambridge 2
Ciserano 2
Delhi 2
Garbagnate Milanese 2
Jinan 2
Legnano 2
Monterotondo 2
Mountain View 2
Naples 2
Nerviano 2
Perugia 2
Pordenone 2
Rho 2
Romano d'Ezzelino 2
Salerno 2
San Severo 2
Seattle 2
Seriate 2
Seveso 2
Sint Odilienberg 2
Southwark 2
Spresiano 2
Strumica 2
Trento 2
Vicenza 2
Washington 2
Woerden 2
Woodbridge 2
Agrate Brianza 1
Amsterdam 1
Bologna 1
Boulder 1
Bratislava 1
Breganzona 1
Brno 1
Cassano Magnago 1
Castelleone 1
Catania 1
Central District 1
Champigny-sur-Marne 1
Chiari 1
Chiswick 1
Corsico 1
Dalmine 1
Totale 894
Nome #
A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib 250
Loss of CDKN2B expression as a potential marker of resistance to CDK4/6 inhibitor in Luminal Breast Cancer cells 187
Synergistic drug combinations prevent resistance in ALK+ anaplastic large cell lymphoma 123
DNA Damage Response (DDR) Is Associated With Treatment-free Remission in Chronic Myeloid Leukemia Patients 88
TWIST1 Upregulation Is a Potential Target for Reversing Resistance to the CDK4/6 Inhibitor in Metastatic Luminal Breast Cancer Cells 76
New advances in liquid biopsy technologies for anaplastic lymphoma kinase (Alk)—positive cancer 74
Novel ALK mutations in EML4::ALK+ NSCLC resistant to TKIs identified by liquid biopsy 72
Evolutionary signatures of human cancers revealed via genomic analysis of over 35,000 patients 62
Characterization of cancer subtypes associated with clinical outcomes by multi-omics integrative clustering 61
New pan-ALK inhibitor-resistant EML4::ALK mutations detected by liquid biopsy in lung cancer patients 55
Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1 53
Effects of blocking CD24 and CD47 'don't eat me' signals in combination with rituximab in mantle-cell lymphoma and chronic lymphocytic leukaemia 47
Synergistic drug combinations preventdrug resistance in anaplastic large cell lymphomapreclinical models 36
Totale 1.184
Categoria #
all - tutte 5.390
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.390


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202047 0 0 0 0 0 0 9 11 10 9 8 0
2020/202196 5 1 13 7 11 12 13 10 8 4 6 6
2021/202269 5 6 4 4 10 5 8 3 7 6 3 8
2022/2023221 20 34 17 17 8 15 1 9 20 33 22 25
2023/2024477 41 22 22 20 59 94 73 16 34 23 30 43
2024/2025274 52 94 88 40 0 0 0 0 0 0 0 0
Totale 1.184